HomeCompareKGHZF vs JNJ

KGHZF vs JNJ: Dividend Comparison 2026

KGHZF yields 250000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KGHZF wins by $4.567699004441311e+30M in total portfolio value
10 years
KGHZF
KGHZF
● Live price
250000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.567699004441311e+30M
Annual income
$4,564,107,688,187,857,300,000,000,000,000,000,000.00
Full KGHZF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — KGHZF vs JNJ

📍 KGHZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKGHZFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KGHZF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KGHZF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KGHZF
Annual income on $10K today (after 15% tax)
$21,250,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,879,491,534,959,678,500,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, KGHZF beats the other by $3,879,491,534,959,678,500,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KGHZF + JNJ for your $10,000?

KGHZF: 50%JNJ: 50%
100% JNJ50/50100% KGHZF
Portfolio after 10yr
$2.2838495022206556e+30M
Annual income
$2,282,053,844,093,928,700,000,000,000,000,000,000.00/yr
Blended yield
99.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

KGHZF
No analyst data
Altman Z
-218.0
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KGHZF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKGHZFJNJ
Forward yield250000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.567699004441311e+30M$30.3K
Annual income after 10y$4,564,107,688,187,857,300,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.567463897060879e+30M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KGHZF vs JNJ ($10,000, DRIP)

YearKGHZF PortfolioKGHZF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$25,010,700$25,000,000.00$10,592$272.30+$25.00MKGHZF
2$58,462,976,402$58,436,214,953.27$11,289$357.73+$58462.97MKGHZF
3$127,722,124,784,416$127,659,569,399,665.92$12,123$472.89+$127722124.77MKGHZF
4$260,784,910,907,288,130$260,648,248,233,768,800.00$13,141$629.86+$260784910907.27MKGHZF
5$497,657,939,618,196,950,000$497,378,899,763,526,240,000.00$14,408$846.81+$497657939618196.94MKGHZF
6$887,590,576,640,622,200,000,000$887,058,082,645,230,600,000,000.00$16,021$1,151.60+$887590576640622208.00MKGHZF
7$1,479,547,418,610,237,200,000,000,000$1,478,597,696,693,231,600,000,000,000.00$18,122$1,588.22+$1.4795474186102372e+21MKGHZF
8$2,305,052,548,351,757,200,000,000,000,000$2,303,469,432,613,844,500,000,000,000,000.00$20,930$2,228.20+$2.3050525483517572e+24MKGHZF
9$3,356,370,330,330,650,300,000,000,000,000,000$3,353,903,924,103,914,000,000,000,000,000,000.00$24,792$3,191.91+$3.3563703303306504e+27MKGHZF
10$4,567,699,004,441,311,000,000,000,000,000,000,000$4,564,107,688,187,857,300,000,000,000,000,000,000.00$30,274$4,689.40+$4.567699004441311e+30MKGHZF

KGHZF vs JNJ: Complete Analysis 2026

KGHZFStock

Pangolin Diamonds Corp., together with its subsidiaries, engages in the acquisition, exploration, and development of mineral properties in Botswana. The company holds interests in the Malatswae Diamond property; and the Motloutse Diamond project that include eight diamond prospecting licenses that covers approximately 3114.1 square kilometers located in Botswana. It also holds interest in the Kweneng project that covers an area of 361 square kilometers located in the Kweneng district. In addition, the company has an option agreement with Yashomann Industries Limited to acquire interest in the PL280/2015 project located in the Central District of Botswana; and joint venture agreement with Yokota-Kikau (Pty) Ltd. Pangolin Diamonds Corp. was incorporated in 2011 and is headquartered in Toronto, Canada.

Full KGHZF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this KGHZF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KGHZF vs SCHDKGHZF vs JEPIKGHZF vs OKGHZF vs KOKGHZF vs MAINKGHZF vs ABBVKGHZF vs MRKKGHZF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.